The sense of stopping migraine prophylaxis.

ABSTRACT:

Introduction

Migraine prophylactic therapy has changed over recent years with the development and approval of monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP) pathway. As new therapies emerged, leading headache societies have been providing guidelines on the initiation and escalation of such therapies. However, there is a lack of robust evidence looking at the duration of successful prophylaxis and the effects of therapy discontinuation. In this narrative review we explore both the biological and clinical rationale for prophylactic therapy discontinuation to provide a basis for clinical decision-making.

Methods

Three different literature search strategies were conducted for this narrative review. These include i) stopping rules in comorbiditi

SUBMITTER: Al-Hassany L 

PROVIDER: S-EPMC9933401 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature